Business
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
The rapid growth of Lantern Pharma’s AI platform could lead to accelerated development of better treatments, greater precision in clinical development, and
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nThe rapid growth of Lantern Pharma’s AI platform could lead to accelerated development of better treatments, greater precision in clinical development, and improved combination regimens with the potential for longer and more durable patient responses.\n\n\n\nLantern's RADR® platform recently surpassed 60 billion data points and is planned to exceed 100 billion data points during 2024 and has been crucial in the expansion of the indications for drug candidate LP-184 and in the accelerated development of LP-284.\n\n\n\nLantern seeks to focus additional data growth efforts of the RADR® platform on: drug sensitivity data, combination treatment outcome data, and biomarker data in rare cancers, and on emerging synthetic lethal targets that are aimed at accelerating the development of new therapies for Lantern and its partners.\n\n\n\nLantern will also enhance the RADR® platform's generative AI capabilities, focusing on molecular optimization and automated feature extraction to improve understanding and prediction of molecular dynamics, safety, and drug-drug interactions.\n\n\n\n \n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced a series of important milestones related to the development, size, and advancement of RADR® -- its proprietary AI platform focused on transforming the cost, pace, and timeline of oncology drug development.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240304409919/en/(Graphic: Business Wire)\n“Every data point we add to RADR® further advances our goal of building the most complete, largest, and most powerful AI platform for oncology drug development. This unparalleled growth in data points provides us with greater and potentially more accurate insights into areas of cancer treatment that have insofar seen little to no progress, while also giving us a solid and cost-advantaged starting point to transform that,” said Panna Sharma, CEO and President of Lantern Pharma. “RADR® has now surpassed 60 billion data points, making innovation in developing cancer therapies potentially more precise, powerful, and comprehensive. Additionally, we continue to automate key areas of the growth in our data collection and curation, leading us to have more successful and la...